ACUTE REPETITIVE SEIZURES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In January 2022, Neurelis, Inc., a biopharmaceutical company, signed an exclusive agreement with Aculys Pharma to commercialize and develop VALTOCO in the Asia Pacific region. Aculys Pharma is a Japan-based company that focuses on commercializing and developing innovations in psychiatry and neurology.
• In July 2020, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced a global partnership with Ovid Therapeutics, a biotechnology company, to develop and commercialize Soticlestat, a potentially effective treatment for rare epilepsy syndromes, including certain forms of acute recurrent seizures.
• In April 2020, UCB S.A., a biopharmaceutical company, announced an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261), an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy